Compare Abeona Therapeutics Inc (ABEO) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs PulteGroup, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while PulteGroup, Inc. trades at $123.65 (market cap $24.75B). The key difference: PulteGroup, Inc. is far larger — about 66.3× Abeona Therapeutics Inc's market cap, and PulteGroup, Inc. pays a 0.8% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | PHM | |
|---|---|---|
Market Cap | $373.32M | $24.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $142.56 |
52-Week Low | $4.17 | $108.00 |
Enterprise Value | $228.22M | $24.71B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
PulteGroup (PHM) trades at $129.92, down 2.81% on the day, amid mixed earnings performance with recent quarterly misses. The stock shows a bullish technical signal with strong moving averages and oversold RSI levels, while fundamentals reflect solid profitability with a 12.14% net margin and attractive valuation at a P/E of 12.71. Recent corporate developments include land acquisition for a new community, signaling growth initiatives.
The outlook is cautiously optimistic, supported by analyst consensus and a $144.17 price target, but risks include margin pressure from incentives and housing market sensitivity to interest rates. Investment appeal hinges on execution of margin recovery and sector momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
